Published in Arthritis Rheum on April 01, 2003
TNFalpha blockade in human diseases: mechanisms and future directions. Clin Immunol (2007) 2.17
Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. Ann Rheum Dis (2005) 1.77
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis (2007) 1.70
Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther (2005) 1.58
Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha. Ann Rheum Dis (2004) 1.56
Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment. Arthritis Res Ther (2004) 1.38
Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies. Ann Rheum Dis (2004) 1.38
The role of tumor necrosis factor-alpha in systemic lupus erythematosus. Arthritis Res Ther (2008) 1.33
Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study. Ann Rheum Dis (2005) 1.29
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006. Ann Rheum Dis (2006) 1.25
Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004. Ann Rheum Dis (2004) 1.24
Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study. Arthritis Res Ther (2004) 1.17
Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study. Arthritis Res Ther (2006) 1.17
Antibodies against cyclic citrullinated peptides in patients affected by rheumatoid arthritis before and after infliximab treatment. Rheumatol Int (2005) 1.06
Type I IFN and TNFα cross-regulation in immune-mediated inflammatory disease: basic concepts and clinical relevance. Arthritis Res Ther (2010) 1.03
Innate pathways to B-cell activation and tolerance. Ann N Y Acad Sci (2010) 0.95
Anticytokine therapies in systemic lupus erythematosus. Immunotherapy (2010) 0.94
Efficacy, safety and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double-blind randomised 2-year study. Ann Rheum Dis (2008) 0.93
Anti-TNFalpha therapy in rheumatoid arthritis and autoimmunity. Rheumatol Int (2004) 0.93
Predictors of infusion reactions during infliximab treatment in patients with arthritis. Arthritis Res Ther (2006) 0.87
Impact of three anti-TNFalpha biologics on existing and emergent autoimmunity in rheumatoid arthritis and spondylarthropathy patients. J Clin Immunol (2008) 0.85
Exposure to nuclear antigens contributes to the induction of humoral autoimmunity during tumour necrosis factor alpha blockade. Ann Rheum Dis (2008) 0.85
Side effects of TNF-α blockers in patients with psoriatic arthritis: evidences from literature studies. Clin Rheumatol (2013) 0.85
Chilblain lupus induced by TNF-α antagonists: a case report and literature review. Clin Rheumatol (2011) 0.82
Synovial Tissue Response to Treatment with TNF Blockers in Peripheral Spondyloarthritis. Open Rheumatol J (2011) 0.79
Correlation between elevation of serum antinuclear antibody titer and decreased therapeutic efficacy in the treatment of Behçet's disease with infliximab. Graefes Arch Clin Exp Ophthalmol (2012) 0.78
Antiphospholipid antibodies during 6-month treatment with infliximab: a preliminary report. Med Sci Monit (2014) 0.78
Recent developments in the use of biologics in psoriasis and autoimmune disorders. The role of autoantibodies. BMJ (2005) 0.77
Pegylated interferon alpha-2B induced lupus in a patient with chronic hepatitis B virus infection: case report. Clin Rheumatol (2009) 0.77
Rheumatoid factor appearance after tocilizumab treatment seems to predict bad therapeutical response in rheumatoid arthritis. Rheumatol Int (2012) 0.77
Possible association of etanercept, venous thrombosis, and induction of antiphospholipid syndrome. Case Rep Rheumatol (2014) 0.75
Overlapping presentation of fungal tubulointerstitial nephritis in an immunosuppressed pediatric patient. Pediatr Nephrol (2009) 0.75
Efficacy, safety, and tolerability of abatacept in the management of rheumatoid arthritis. Open Access Rheumatol (2009) 0.75
Immune-regulatory mechanisms in systemic autoimmune and rheumatic diseases. Clin Dev Immunol (2011) 0.75
The changing face of spondyloarthropathies under TNF α blockade. Open Rheumatol J (2008) 0.75
Randomized controlled trial of adalimumab in patients with nonpsoriatic peripheral spondyloarthritis. Arthritis Rheumatol (2015) 4.41
Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum (2002) 2.44
Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy. Arthritis Rheum (2002) 2.35
DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatment. Arthritis Res Ther (2005) 1.96
Automated indirect immunofluorescence antinuclear antibody analysis is a standardized alternative for visual microscope interpretation. Clin Chem Lab Med (2013) 1.75
Management of inflammatory bowel disease in pregnancy. J Crohns Colitis (2012) 1.69
Identification of synovial biomarkers of response to experimental treatment in early-phase clinical trials in spondylarthritis. Arthritis Rheum (2006) 1.62
(99)mTc-(CO)(3) His-annexin A5 micro-SPECT demonstrates increased cell death by irinotecan during the vascular normalization window caused by bevacizumab. J Nucl Med (2011) 1.55
Diagnostic performance and predictive value of rheumatoid factor, anti-citrullinated peptide antibodies, and the HLA shared epitope for diagnosis of rheumatoid arthritis. Clin Chem (2004) 1.53
Synovial histopathology of psoriatic arthritis, both oligo- and polyarticular, resembles spondyloarthropathy more than it does rheumatoid arthritis. Arthritis Res Ther (2005) 1.52
Meniscal allograft transplantation: long-term clinical results with radiological and magnetic resonance imaging correlations. Knee Surg Sports Traumatol Arthrosc (2006) 1.46
Synovial intracellular citrullinated proteins colocalizing with peptidyl arginine deiminase as pathophysiologically relevant antigenic determinants of rheumatoid arthritis-specific humoral autoimmunity. Arthritis Rheum (2005) 1.42
Systemic levels of IL-23 are strongly associated with disease activity in rheumatoid arthritis but not spondyloarthritis. Ann Rheum Dis (2009) 1.39
Fibrin deimination in synovial tissue is not specific for rheumatoid arthritis but commonly occurs during synovitides. J Immunol (2005) 1.37
Macrophages expressing the scavenger receptor CD163: a link between immune alterations of the gut and synovial inflammation in spondyloarthropathy. J Pathol (2002) 1.34
Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and down-regulation by tumor necrosis factor alpha blockade in spondylarthropathy. Arthritis Rheum (2004) 1.29
Accuracy of anti-ribosomal P protein antibody testing for the diagnosis of neuropsychiatric systemic lupus erythematosus: an international meta-analysis. Arthritis Rheum (2006) 1.21
Infiltration of the synovial membrane with macrophage subsets and polymorphonuclear cells reflects global disease activity in spondyloarthropathy. Arthritis Res Ther (2005) 1.21
Differential expression and response to anti-TNFalpha treatment of infiltrating versus resident tissue macrophage subsets in autoimmune arthritis. J Pathol (2005) 1.21
Diagnostic classification of spondylarthropathy and rheumatoid arthritis by synovial histopathology: a prospective study in 154 consecutive patients. Arthritis Rheum (2004) 1.19
The epidemiology of ankylosing spondylitis and the commencement of anti-TNF therapy in daily rheumatology practice. Ann Rheum Dis (2007) 1.14
Clues to pathogenesis of spondyloarthropathy derived from synovial fluid mononuclear cell gene expression profiles. J Rheumatol (2002) 1.12
Serum levels of matrix metalloproteinase 3 and macrophage colony-stimulating factor 1 correlate with disease activity in ankylosing spondylitis. Arthritis Rheum (2004) 1.12
Tumor necrosis factor alpha blockade treatment down-modulates the increased systemic and local expression of Toll-like receptor 2 and Toll-like receptor 4 in spondylarthropathy. Arthritis Rheum (2005) 1.12
Identification of citrullinated rheumatoid arthritis-specific epitopes in natural filaggrin relevant for antifilaggrin autoantibody detection by line immunoassay. Arthritis Rheum (2002) 1.12
Diagnostic value of anti-human citrullinated fibrinogen ELISA and comparison with four other anti-citrullinated protein assays. Arthritis Res Ther (2006) 1.12
Transplantation of viable meniscal allograft. Survivorship analysis and clinical outcome of one hundred cases. J Bone Joint Surg Am (2005) 1.12
Nailfold capillaroscopy for prediction of novel future severe organ involvement in systemic sclerosis. J Rheumatol (2013) 1.10
Vaccinations in patients with immune-mediated inflammatory diseases. Rheumatology (Oxford) (2010) 1.10
Relevance of different results of different anti-double-stranded DNA assays in reporting clinical studies: comment on the article by Petri et al. Arthritis Rheumatol (2014) 1.08
Noninvasive monitoring of radiotherapy-induced microvascular changes using dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) in a colorectal tumor model. Int J Radiat Oncol Biol Phys (2006) 1.07
Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis. Arthritis Rheum (2005) 1.06
Association of CD163+ macrophages and local production of soluble CD163 with decreased lymphocyte activation in spondylarthropathy synovitis. Arthritis Rheum (2004) 1.06
Gut inflammation and spondyloarthropathies. Curr Rheumatol Rep (2002) 1.06
Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity. Arthritis Res Ther (2006) 1.05
Spinal radiographic changes in ankylosing spondylitis: association with clinical characteristics and functional outcome. J Rheumatol (2009) 1.03
Detection of major histocompatibility complex/human cartilage gp-39 complexes in rheumatoid arthritis synovitis as a specific and independent histologic marker. Arthritis Rheum (2004) 1.02
Reliability of the qualitative and semiquantitative nailfold videocapillaroscopy assessment in a systemic sclerosis cohort: a two-centre study. Ann Rheum Dis (2010) 1.02
Citrullinated vimentin as an important antigen in immune complexes from synovial fluid of rheumatoid arthritis patients with antibodies against citrullinated proteins. Arthritis Res Ther (2010) 0.99
Detection of microsatellite instability in colorectal cancer using an alternative multiplex assay of quasi-monomorphic mononucleotide markers. J Mol Diagn (2008) 0.99
Chronically inflamed synovium from spondyloarthropathy and rheumatoid arthritis investigated by protein expression profiling followed by tandem mass spectrometry. Proteomics (2005) 0.99
Novel autoantibody markers for early and seronegative rheumatoid arthritis. J Autoimmun (2010) 0.98
Localization of MHC class II/human cartilage glycoprotein-39 complexes in synovia of rheumatoid arthritis patients using complex-specific monoclonal antibodies. J Immunol (2003) 0.97
Effects of intra-articular corticosteroids and anti-TNF therapy on neutrophil activation in rheumatoid arthritis. Ann Rheum Dis (2007) 0.97
Immunomodulatory effects of etanercept on peripheral joint synovitis in the spondylarthropathies. Arthritis Rheum (2005) 0.96
Cancer risk in immune-mediated inflammatory diseases (IMID). Mol Cancer (2013) 0.95
Degree of bone marrow oedema in sacroiliac joints of patients with axial spondyloarthritis is linked to gut inflammation and male sex: results from the GIANT cohort. Ann Rheum Dis (2013) 0.94
Growth differentiation factor 15, a marker of lung involvement in systemic sclerosis, is involved in fibrosis development but is not indispensable for fibrosis development. Arthritis Rheumatol (2014) 0.94
CARD15 variants determine a disturbed early response of monocytes to adherent-invasive Escherichia coli strain LF82 in Crohn's disease. Int J Immunogenet (2007) 0.92
Ankylosing spondylitis and bowel disease. Best Pract Res Clin Rheumatol (2002) 0.91
The Belgian MIRA (MabThera In Rheumatoid Arthritis) registry: clues for the optimization of rituximab treatment strategies. Arthritis Res Ther (2010) 0.91
Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy. Arthritis Res Ther (2010) 0.91
Rheumatoid arthritis and pregnancy: evolution of disease activity and pathophysiological considerations for drug use. Rheumatology (Oxford) (2011) 0.90
Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions? Acta Gastroenterol Belg (2008) 0.89
Expression of SGLT1, Bcl-2 and p53 in primary pancreatic cancer related to survival. Cancer Invest (2008) 0.89
Optimal approaches to data collection and analysis of potential immune mediated disorders in clinical trials of new vaccines. Vaccine (2013) 0.88
Detection of specific antinuclear reactivities in patients with negative anti-nuclear antibody immunofluorescence screening tests. Clin Chem (2002) 0.88
In vivo imaging of apoptosis in oncology: an update. Mol Imaging (2011) 0.88
Distinct synovial immunopathologic characteristics of juvenile-onset spondylarthritis and other forms of juvenile idiopathic arthritis. Arthritis Rheum (2006) 0.88
Gut inflammation in the spondyloarthropathies. Curr Rheumatol Rep (2005) 0.88
Single-photon emission computed tomographic imaging of the early time course of therapy-induced cell death using technetium 99m tricarbonyl His-annexin A5 in a colorectal cancer xenograft model. Mol Imaging (2012) 0.87